COMMUNIQUÉS West-GlobeNewswire

Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors
16/11/2017
MORRISTOWN, N.J., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX ) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the election of two new directors to [...]
Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
16/11/2017
NOVATO, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today [...]
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
16/11/2017
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO ), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for [...]
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
16/11/2017
Pharmacokinetic Bioequivalence Shown for Cytori’s ATI-0918 Liposomal Formulation of Doxorubicin Hydrochloride, Results Presented at the 2017 American Association of Pharmaceutical Scientists Annual Meeting SAN DIEGO, [...]
Prothena Highlights Breadth of Novel Pipeline at R&D Day
16/11/2017
Clinical development programs advancing toward key milestones Dr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNP Novel discovery pipeline in [...]
Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
16/11/2017
BEVERLY, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide additional perspectives on the planned [...]
Interpace Diagnostics Announces New York State Approval of New Product
16/11/2017
PARSIPPANY, N.J., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Corp. (NASDAQ: IDXG ), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services [...]
Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
16/11/2017
PETALUMA, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the [...]
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
16/11/2017
All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate, Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa, Nov. 16, 2017 (GLOBE NEWSWIRE) -- [...]
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)
16/11/2017
NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that data [...]
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
16/11/2017
Combined Company Commences Trading on the Nasdaq Global Market on November 16, 2017 under the Ticker Symbol “ARCT” Approximately $50.1 Million in Net Cash Following Closing of the Merger Ten (10) Pipeline Programs, Six [...]
MediWound Reports Third Quarter 2017 Financial Results
16/11/2017
NexoBrid ® sales grow 74% year-to-date Raised gross proceeds of $25.2 million through public equity offering Awarded additional $32 million from BARDA to support NexoBrid R&D programs Conference call begins today at [...]
LHC Group and Almost Family Announce Merger of Equals to Create Leading National Provider of In-Home Healthcare Services
16/11/2017
National platform enables greater service and continuity across continuum of care Well-positioned to lead the transition to value-based reimbursement through the highest quality and patient satisfaction Immediately [...]
Purepoint Uranium Group Inc: Hook Lake JV Partners Approve $4 Million For 2018 Exploration Budget
16/11/2017
TORONTO, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “ Company ” or “ Purepoint ”) (TSX:PTU.V) announced today that the proposed 2018 Hook Lake JV exploration program with a budgeted cost of $4, [...]
Merit Medical Signs Purchase Agreement with BD for Divestment Assets
16/11/2017
SOUTH JORDAN, Utah, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI ), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic [...]
BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference
16/11/2017
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today that executives from the Company are scheduled to provide a corporate summary and update [...]
Orphazyme A/S: Major shareholder announcement
16/11/2017
Company announcement Orphazyme A/S No. 10/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 16 November 2017 Major shareholder announcement With reference to company [...]
Orphazyme A/S: Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Orphazymes' shares
16/11/2017
Company announcement Orphazyme A/S No. 9/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 16 November 2017 Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S [...]
Orphazyme A/S: New share-based incentive programme
16/11/2017
Company announcement Orphazyme A/S No. 8/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 16 November 2017 With reference to the offering circular (the "Offering Circular [...]

Pages